Takeda announces interim results for Takhzyro, aims to launch it in more countries June 12, 2020 By Gina Lee HONG KONG – Takeda Pharmaceutical Co. Ltd. is preparing to take Takhzyro (lanadelumab) to the world stage after announcing its interim results for a phase III hereditary angioedema long-term prophylaxis (HELP) study.Read More
Pfizer reports topline data from JADE TEEN trial of abrocitinib in adolescent atopic dermatitis June 10, 2020
Lumosa initiates phase I/II study of LT-5001 for uremic pruritus in hemodialysis patients June 8, 2020
First-in-human data for B-VEC in patients with recessive dystrophic epidermolysis bullosa May 28, 2020
FDA approves Dupixent for moderate to severe atopic dermatitis in children aged 6-11 years May 27, 2020
ATx-201 found safe and able to improve skin barrier function biomarkers in phase II study May 27, 2020
RSS
